注册 登录  
 加关注
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

liusongjifan2的博客

读书是同智者交流;读书是对神奇世界的探访;读书是和挚友娓娓谈心 !

 
 
 

日志

 
 

【转载】The Lancet -Oncology(Weekly Update)  

2016-02-16 13:04:28|  分类: 医学知识 |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |
Logo
Weekly Update
February 15, 2016
Weekly Features:
Steve Gschmeissner/Science Photo Library
Research | Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer
The GeparSepto (GBG 69) trial assessed whether weekly nab-paclitaxel could increase the proportion of patients achieving pathological complete response compared with weekly solvent-based paclitaxel.
Read this Article →
Podcast
Podcast | NAB-paclitaxel and breast cancer
In this month's The Lancet Oncologypodcast, Sibylle Loibl discusses the findings and clinical implications of the GeparSepto trial.
Listen to this podcast →
Subscribe to podcast →
Online First:
alt text here
NEWS
FDA confronts opioid addiction and overdose deaths
Faced with a growing nationwide epidemic of opioid drug addiction and overdose deaths, the Food and Drug Administration (FDA) has announced a comprehensive review of the agency's opioids policies.
Read this Report →
alt text here
NEWS
Oncologic Drugs Advisory Committee and conflicts of interest
Almost a third of public speakers at meetings of the US Oncologic Drugs Advisory Committee (ODAC) have a financial relation with the company seeking drug approval, according to new research.
Read this Report →
alt text here
NEWS
Association between allergies and reduced risk of glioma
Authors of a new study have noted an inverse association between the risk of developing glioma and a history of allergies.
Read this Report →
alt text here
COMMENT
HER2-positive breast cancer: is more treatment better?
Hope Rugo and Jo Chien comment on Chan and colleagues' phase 3 trial of neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET).
Read this Comment →
alt text here
ARTICLES
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. Chan and colleagues aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer.
Read this Article →
STEVE GSCHMEISSNER/SCIENCE PHOTO LIBRARY
COMMENT
Extranodal natural killer T-cell lymphoma—new profiling, old tricks
Andrei Shustov comments on Seok Jin Kim and colleagues' assessment of a new clinical–pathological prognostic index, the prognostic index of natural killer lymphoma (PINK).
Read this Comment →
alt text here
ARTICLES
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis
The clinical outcome of extranodal natural killer T-cell lymphoma (ENKTL) has improved substantially as a result of new treatment strategies with non-anthracycline-based chemotherapies and upfront use of concurrent chemoradiotherapy or radiotherapy. Seok Jin Kim and colleagues propose a new prognostic model based on the outcomes obtained with these contemporary treatments.
Read this Article →
STEVE GSCHMEISSNER/SCIENCE PHOTO LIBRARY
COMMENT
Neoadjuvant nab-paclitaxel in breast cancer: trial results and patient care
Marco Colleoni comments on the results of the GeparSepto (GBG 69) trial, which assessed whether weekly nab-paclitaxel could increase the proportion of patients achieving pathological complete response compared with weekly solvent-based paclitaxel.
Read this Comment →
alt text here
ARTICLES
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial
The GeparSepto (GBG 69) trial assessed whether weekly nab-paclitaxel could increase the proportion of patients achieving pathological complete response compared with weekly solvent-based paclitaxel.
Read this Article →
Announcements:
Alerts
Stay Connected
You are receiving our new The Lancet Oncology Weekly Update as an extension to the Table of Contents alert service to which you are subscribed. We hope that you find this weekly roundup of breaking news, comment, and research informative and useful.

If you would prefer not to receive these weekly updates, but wish to continue receiving the monthly Table of Contents alert, please click here:
Unsubscribe from Weekly Updates →

For all the very latest news, comment, and research follow The Lancet Oncology on Twitter.
Follow us →
【转载】The Lancet -Oncology(Weekly Update) - liusongjifan2 - liusongjifan2的博客
This email has been sent from The Lancet, Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, registered in England with registered number 1982084. 

Copyright ? 2016 Elsevier Limited. All rights reserved. THE LANCET ? is a registered trademark of RELX Intellectual Properties SA, used under license. 

To unsubscribe from The Lancet Oncology Weekly Updates, but continue receiving the monthly Table of Contents alert, please click here →

To unsubscribe from all Table of Contents alerts, please edit your mailing preferences by logging in to your TheLancet.com account: 

Update mailing preferences
  评论这张
 
阅读(4)| 评论(0)
推荐 转载

历史上的今天

在LOFTER的更多文章

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2017